Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s):  CLAZF

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID... see more

TSXV:CLAS.H - Post Discussion

Claritas Pharmaceuticals Inc > here's the limk
View:
Post by HighSkies2019 on Sep 11, 2020 10:11am

here's the limk

https://tcbiznews.com/news/19081/non-union-fractures-market-to-eyewitness-massive-growth-by-2026-leading-key-players-daniel-c-allisonregenexxkalytera-therapeutics-inc-asa-srlmesentech/#
Comment by ETalien on Sep 11, 2020 10:31am
Thanks! :)
Comment by JMark80 on Sep 11, 2020 11:04am
LMAO. Kalytera terminated that indication, among many others, 2 years ago.
Comment by JMark80 on Sep 11, 2020 2:12pm
GvHD, Acute Respiratory Distress Syndrome, Ulcerative Colitis, Psoriasis, Dysmenorrhea, Uveitis, Pain, Osteoporosis, Osteogenesis Imperfecta, Atopic Dermatitis, Acne. Am I missing any? LMAO
Comment by JMark80 on Sep 11, 2020 2:16pm
Oh wait, I am! Anyone remember K-1052, the Inducible Nitric Oxide Synthase Inhibitor for Sepsis Associated Renal Failure & Severe Traumatic Brain Injury? Of course you don't! LMAO
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities
USER FEEDBACK SURVEY ×

Be the voice that helps shape the content on site!

At Stockhouse, we’re committed to delivering content that matters to you. Your insights are key in shaping our strategy. Take a few minutes to share your feedback and help influence what you see on our site!

The Market Online in partnership with Stockhouse